Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Approved for marketing × Amifampridine × 1 year × Clear all

Status

Approved for marketing 1

Sponsor Class

Study Type

Expanded_access 1

Sponsor

Conditions

Nystagmus, Pathologic 1 Myasthenic Syndromes, Congenital 1 Lambert-Eaton Myasthenic Syndrome 1

Interventions

zenocutuzumab 1 tucatinib 1 talquetamab 1 niraparib 1 futibatinib 1 erdafitinib 1 cemiplimab 1 adagrasib 1 Trastuzumab 1 TIC10 compound 1 Prednisone 1 Prednisolone 1 Capecitabine 1 Amifampridine 1 Abiraterone Acetate 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02189720 2025-03-26

EAP-001

Catalyst Pharmaceuticals, Inc.

Approved for marketing

Nystagmus, Pathologic, Lambert-Eaton Myasthenic Syndrome, Myasthenic Syndromes, Congenital

Data powered by HemOnc (CC BY 4.0) Colophon ⚡